Drug profile · INN
leniolisib phosphate
JOENJA
leniolisib phosphate (JOENJA) is a pi3-kinase p110-delta subunit inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — leniolisib phosphate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
leniolisib phosphate (JOENJA) is a pi3-kinase p110-delta subunit inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
PI3-kinase p110-delta subunit inhibitor
Primary target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is leniolisib phosphate?
leniolisib phosphate (JOENJA) is a pi3-kinase p110-delta subunit inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for leniolisib phosphate?
JOENJA is a marketed brand name for leniolisib phosphate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of leniolisib phosphate?
leniolisib phosphate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.